Cencora, Inc. (COR)
(Delayed Data from NYSE)
$224.81 USD
+2.25 (1.01%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $224.79 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Price, Consensus and EPS Surprise
COR 224.81 +2.25(1.01%)
Will COR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for COR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COR
Here's Why Cencora (COR) is a Strong Growth Stock
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
COR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Cencora (COR) is a Top Growth Stock for the Long-Term
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Other News for COR
Morgan Stanley Keeps Their Hold Rating on Cencora (COR)
IYH: Healthcare Dashboard For October
TimesSquare U.S. Mid Cap Growth Strategy Q3 2024 Commentary
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,700 Today
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff